Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01585766 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01585766 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 56 participants.
The verdict
NCT01585766, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of ascending intravenous (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of multiple sclerosis (MS).
Interventions
- DRUG MEDI-551 30 MG-IV
- DRUG MEDI-551 60 MG-SC
- DRUG PLACEBO-IV-SC
- DRUG MEDI-551 100 MG-IV
- DRUG MEDI-551 300 MG-SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-04-24 |
| Est. Completion | 2016-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01585766
The ClinicalTrials.gov registry entry for NCT01585766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MEDI-551 30 MG-IV is the first listed.
NCT01585766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01585766 about?
NCT01585766 is a clinical study titled "Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis". The purpose of this study is to evaluate the safety and tolerability of ascending intravenous (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of multiple sclerosis (MS).
What is the current status of trial NCT01585766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2012-04-24. Estimated completion is 2016-06-20.
What interventions are being tested in trial NCT01585766?
The interventions under investigation include: MEDI-551 30 MG-IV (DRUG), MEDI-551 60 MG-SC (DRUG), PLACEBO-IV-SC (DRUG), MEDI-551 100 MG-IV (DRUG), MEDI-551 300 MG-SC (DRUG).
Who is sponsoring clinical trial NCT01585766?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.